The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper examines the effect of the quality of medical care, behavioral risk factors (obesity, smoking, and AIDS incidence), and other variables (education, income, and health insurance coverage) on life expectancy and medical expenditure using longitudinal statelevel data. We examine the effects of three different measures of the quality of medical care. The first is the average quality of diagnostic imaging procedures, defined as the fraction of procedures that are advanced procedures. The second is the average quality of practicing physicians, defined as the fraction of physicians that were trained at top-ranked medical schools. The third is the mean vintage (FDA approval year) of outpatient and inpatient prescription drugs. Life expectancy increased more rapidly in states where (1) the fraction of Medicare diagnostic imaging procedures that were advanced procedures increased more rapidly; (2) the vintage of self-and provider-administered drugs increased more rapidly; and (3) the quality of medical schools previously attended by physicians increased more rapidly. States with larger increases in the quality of diagnostic procedures, drugs, and physicians did not have larger increases in per capita medical expenditure. We perform several tests of the robustness of the life expectancy model. Controlling for per capita health expenditure (the "quantity" of healthcare), and eliminating the influence of infant mortality, has virtually no effect on the healthcare quality coefficients. Controlling for the adoption of an important nonmedical innovation also has little influence on the estimated effects of medical innovation adoption on life expectancy.
During the twentieth century, U.S. life expectancy at birth increased by almost 30 years (63%), from 47.3 years in 1900 to 77.0 years in 2000. Nordhaus (2002) estimated that, "to a first approximation, the economic value of increases in longevity over the twentieth century is about as large as the value of measured growth in non-health goods and services" (p. 17). Murphy and Topel (2005) observed that "the historical gains from increased longevity have been enormous. Over the 20th century, cumulative gains in life expectancy were worth over $1.2 million per person for both men and women. Between 1970 and 2000 increased longevity added about $3.2 trillion per year to national wealth, an uncounted value equal to about half of average annual GDP over the period."
The rate of increase in longevity has varied considerably across states. Figure 1 shows the increase in life expectancy at birth during the period [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] 1 by state. In the eight states with the smallest increase, life expectancy increased by only 0.31-1.16 years. In the eight states with the largest increase, life expectancy increased by 2.5-4.3 years. This paper seeks to help answer the question, why has longevity increased faster in some states than other states?
Longevity is likely to depend on a number of factors, including the quality of medical care, exogenous changes in disease incidence (e.g. the appearance of new diseases such as HIV/AIDS), income, education, and behavioral risk factors (e.g., obesity and smoking). By analyzing longitudinal state-level data, we can measure and control for many of these factors. We can also control for the effects of unobserved factors that vary across states but are relatively stable over time (e.g. climate and environmental quality), and unobserved factors that change over time but are invariant across states (e.g. changes in Federal government policies). In addition to interstate variation in longevity growth, we will analyze the growth of per capita medical expenditure. The overall conceptual framework of the paper is depicted in Fig. 2 . Previous literature suggests that technological innovation in general, and new goods in particular, play a key role in economic growth. In "Indicators of the quality of medical care" section, we describe our indicators of the quality of medical care. "Econometric model" section describes the econometric models we will estimate. "Data sources and descriptive statistics" section describes the data sources and presents some descriptive statistics. Empirical results are presented in "Empirical results" section. Estimates of some additional life expectancy equations to assess the robustness of the estimates are presented in "Robustness checks" section. The final section presents a summary and conclusions.
Indicators of the quality of medical care
We will examine the effects of three different measures of the quality of medical care. The first is the average quality of diagnostic imaging procedures, defined as the fraction of procedures that are advanced procedures. The second is the average quality of practicing physicians, defined as the fraction of physicians that were trained at top-ranked medical schools. The third is the mean vintage (FDA approval year) of outpatient and impatient prescription drugs.
Some of the indicators of the quality of medical care we examine measure the relative utilization of new versus old medical goods and services, or the degree of influence of medical research. Economists believe that new goods and services, which are generated by public and private investment in research and development, are the main reason why people are better off today than they were several generations ago. Grossman and Helpman (1993) argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." Bresnahan and Gordon (1996) stated simply that "new goods are at the heart of economic progress." Jones (1998) argues that "technological progress [is] the ultimate driving force behind sustained economic growth" (p. 2), and that "technological progress is driven by research and development (R&D) in the advanced world" (p. 89). Bils (2004) makes the case that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models."
One way to measure utilization of medical innovations is to measure the mean vintage of medical goods and services used. The vintage of a good is the year in which the good was first used. For example, the vintage of the drug atorvastatin (Lipitor) is 1997-the year the drug was approved by the FDA. We seek to test the hypothesis that, ceteris paribus, people using newer, or later vintage, medical goods and services will be in better health, and will therefore live longer. This hypothesis is predicated on the idea that these goods and services, like other R&D intensive products, are characterized by embodied technological progress. 2 A number of econometric studies (Bahk and Gort 1993; Hulten 1992; Wilson 2001, 2004) have investigated the hypothesis that capital equipment employed by U.S. manufacturing firms embodies technological change, i.e. that each successive vintage of investment is more productive than the last. Equipment is expected to embody significant technical progress due to the relatively high R&D-intensity of equipment manufacturers. The method that has been used to test the equipment-embodied technical change hypothesis is to estimate manufacturing production functions, including (mean) vintage of equipment as well as quantities of capital and labor. These studies have concluded that technical progress embodied in equipment is a major source of manufacturing productivity growth.
Although most previous empirical studies of embodied technical progress have focused on equipment used in manufacturing, embodied technical progress may also be an important source of economic growth in health care. According to the National Science Foundation, in 1997, "medical substances and devices firms had by far the highest combined R&D intensity at 11.8%,…well above the 4.2-percent average for all 500 top 1997 R&D spenders combined. The information and electronics sector ranked second in intensity at 7.0%." 3
Quality of diagnostic imaging procedures
Our measure of the quality of diagnostic imaging procedures is defined as follows: Solow (1960, p. 91) : argued that "many if not most innovations need to be embodied in new kinds of durable equipment before they can be made effective. Improvements in technology affect output only to the extent that they are carried into practice either by net capital formation or by the replacement of old-fashioned equipment by the latest models…" We hypothesize that innovations may be embodied in nondurable goods (e.g. drugs) and services as well as in durable equipment. 20% 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 , 1991-2004 Physician/Supplier Procedure Summary Master Files. 6 These files are 100% summaries of all Part B Carrier and DMERC Claims processed through the Common Working File and stored in the National Claims History Repository.
We used Berenson-Eggers Type of Service (BETOS) codes developed by CMS to distinguish between standard and advanced imaging procedures. The BETOS coding system was developed primarily for analyzing the growth in Medicare expenditures. The coding system covers all HCPCS codes; assigns a HCPCS code to only one BETOS code; consists of readily understood clinical categories (as opposed to statistical or financial categories); consists of categories that permit objective assignment; is stable over time; and is relatively immune to minor changes in technology or practice patterns. 7 Advanced imaging procedures (with a BETOS code beginning with I2) involve either a computed tomography (CT) scan 8 or magnetic resonance imaging (MRI). 9 Standard imaging procedures have BETOS codes beginning with I1.
According to the 2006 BETOS Public Use File, 544 HCPCS codes correspond to standard imaging procedures, and 152 HCPCS codes correspond to advanced imaging procedures. For example, code 71010 (Radiologic examination, chest; single view, frontal) is a standard imaging procedure, and code 70450 (Computed tomography, head or brain; without contrast material) is an advanced imaging procedure.
As shown in Fig. 3 , nationwide the fraction of imaging procedures that were advanced increased from 9.3% in 1991 to 18.8% in 2004. As shown in Fig. 4 , the fraction of imaging procedures that were advanced in 2004 was 16-17% in the lowest six states, and 20-24% in the highest six states.
6 http://www.cms.hhs.gov/NonIdentifiableDataFiles/06_PhysicianSupplierProcedureSummaryMasterFile. asp. 7 http://www.cms.hhs.gov/HCPCSReleaseCodeSets/20_BETOS.asp#TopOfPage. 8 A computed tomography scan is a study that uses a series of X-Rays to create image "slices" of the body. 9 MRI is a medical imaging technique most commonly used in radiology to visualize the structure and function of the body. It provides detailed images of the body in any plane. MRI provides much greater contrast between the different soft tissues of the body than CT does, making it especially useful in neurological (brain), musculoskeletal, cardiovascular, and oncological (cancer) imaging. Physician quality
Our measure of the quality of practicing physicians is the fraction of physicians practicing in a state that graduated from a top-ranked medical school. Data on the number of practicing physicians, by state, medical school attended, and year, were obtained from the American Medical Association. Medical school rankings in terms of research and primary care were obtained from the US News and World Report survey of U.S. medical schools conducted in Fall 2007. The medical school research ranking is based on a weighted average of eight indicators, and the primary-care ranking is based on seven indicators. Both rankings are based on a weighted average of indicators; four of the data indicators are used in both the research and primary-care ranking model. The research ranking factors in research activity; the primary-care ranking adds a measure of the proportion of graduates entering primary-care specialties. The methodology underlying the rankings is described in Appendix A. As shown in Table 1 , research rank and primary care rank are not highly correlated. We constructed two measures of physician quality:
where MD_RESEARCH_QUAL st = the fraction of physicians practicing in state s in year t who were graduates from the top 60 medical schools ranked in terms of research. MD_PRIMCARE_QUAL st = the fraction of physicians practicing in state s in year t who were graduates from the top 60 medical schools ranked in terms of primary care. TOP_RESEARCH m = 1 if medical school m was one of the top 60 medical schools ranked in terms of research; = 0 otherwise. Adjusting for state-specific changes in the distribution of disease If there have been state-specific changes in the distribution of disease, and drug vintage is correlated with disease severity (e.g., newer drugs tend to be for less severe diseases), the coefficient on drug vintage could be biased. However, we can eliminate any potential bias by constructing an alternative (fixed-weighted) index of drug vintage.
Consider the following simplified model of life expectancy:
where LE = life expectancy, V = drug vintage, and S = (mean) disease severity. Hence
Suppose that β 1 > 0 and that β 2 < 0. For simplicity, suppose that there are just 2 diseases: a high-severity disease and a low-severity disease. Mean disease severity depends on the proportions of patients with each disease:
where high% = the percent of patients with the high-severity disease, S H = severity of the high-severity disease, S L = severity of the low-severity disease, and S H > S L . Assuming that S H and S L are constant, S = (S H − S L ) high%, and
The change in life expectancy is directly related to the change in drug vintage and inversely related to the change in the percent of patients with the high-severity disease. Suppose that drugs for the low-severity disease (nervous system disorders) tend to be newer than drugs for the high-severity disease (cardiovascular disease), so that there is an inverse correlation across states between V and high%: states with smaller increases in mean severity will have larger increases in drug vintage. In this case, failure to control for changes in severity ( high%) will result in overestimation of the effect of drug vintage on life expectancy.
We will control for the incidence of one highly severe disease-AIDS-but unfortunately data on the incidence of other diseases, by state and year, are not available. Therefore direct measurement of mean disease severity (or the percent of patients with high-severity diseases) by state and year is not feasible. However, provided that the distribution of drugs utilized, by therapeutic class, is closely related to the distribution of patients, by disease, we can eliminate any potential bias in the vintage coefficient by using the following fixed-weighted index of drug vintage:
where V cit = the mean vintage of prescriptions in therapeutic class c in state i in year t, and class% ci. = the mean fraction of prescriptions in therapeutic class c in state i during the entire sample period, i.e. class% ci. = (1 / T) t class% cit , where class% cit = the fraction of prescriptions in therapeutic class c in state i in year t.
Changes over time in the fixed-weighted index V' are entirely due to within-therapeutic class changes in drug vintage, not at all to between-class changes, i.e. shifts in the distribution of drugs by therapeutic class. In contrast, changes in the standard vintage index (V it = c class% cit V cit ) are due to between-as well as within-class changes in vintage.
We will construct fixed-weighted indices of drug vintage using data from the Veterans Administration's National Drug File (U.S. Department of Veterans Affairs 2007) on the therapeutic class of each product. The VA drug classification is hierarchical, and has over 500 classes and subclasses. We will classify drugs at the highest level of the VA classification system, which has 32 classes. Table 3 We will estimate models using both the standard index and the fixed-weighted index of drug vintage. Performing this sensitivity analysis is useful, but eliminating the effects of shifts in the distribution of drugs by therapeutic class on vintage is not necessarily appropriate. If the rate of innovation varies across diseases/drug classes, states may benefit from innovation by changing the distribution of drugs consumed, by class, as well as by using newer drugs within drug classes.
Potential reasons for variation in the rate of increase of drug vintage
The rate of increase in drug vintage may vary across states due to both interstate differences in the types of diseases afflicting the population, and differences in the drugs used to treat given diseases. Suppose that Even if the increase in the mean vintage of drugs to treat each disease is the same in every state, differences in the fractions of state residents who have various diseases (share di ) will result in interstate variation in the increase in the mean vintage of drugs. 11 The relative incidence of various diseases does vary across states. This is illustrated by Fig. 7 , which plots the state-level incidence rate (cases per 100,000) of colon & rectum cancer against the incidence rate of prostate cancer for males in 2002. The correlation across states between these two incidence rates is not significantly different from zero ( p-value = 0.61).
Moreover, due to medical practice variation, the increase in the mean vintage of drugs to treat any given disease is likely to vary across states. Medical practice variation is a welldocumented phenomenon: there are 2514 citations for this term in the PubMed database. The Dartmouth Atlas of Health Care Project (Wennberg 2006) has demonstrated "glaring variations in how health care is delivered across the United States." Skinner and Staiger (2005) argue that medical practice variation may be partly due to variation in the frequency and likelihood of informational exchanges through networks or other social activities, which may in turn be related to both average educational attainment and other measures of social capital. They compared the adoption of several important innovations during the 20th century, ranging from advances at mid-century in hybrid corn and tractors, to medical innovations in the treatment of heart attacks at the end of the century. They found a very strong state-level correlation with regard to the adoption of new and effective technology, and this correlation held across a variety of industries and time periods. These results are suggestive of state-level factors associated with barriers to adoption. These barriers may be related to information or network flows, given that farmers, physicians, and individual computer users conduct their business in often small and isolated groups, and therefore are most vulnerable to potential information asymmetries.
Interstate differences in government health care policy also contribute to practice variation. In the last few years, some state Medicaid programs and private managed care plans have restricted access to certain drugs, especially newer, more expensive drugs. One important type of restriction is a "prior authorization" requirement: a prescription will not be dispensed without prior authorization by program officials. Lichtenberg (2005) examined the effect of access restrictions on the vintage of drugs used by Medicaid enrollees. The sample included 50 brand name drugs in six important therapeutic classes: antidepressants, antihypertensives, cholesterol-lowering drugs, diabetic drugs, osteoporosis/menopause drugs, and pain management medications. The extent of access restrictions varied considerably across states. Twelve states did not restrict any of the 50 drugs. Five states restricted over 47% of the drugs, and one-Vermont-restricted 43 of the 50 drugs. The vintage of Medicaid prescriptions increased more slowly in states that imposed more access restrictions. 12
Econometric model
We will investigate the effects of indicators of the quality of medical care, behavioral risk factors, and other variables on life expectancy and medical expenditure by estimating models of the following form: . . ., 50; t = 1991, . . ., 2004) ( 1) where Y is one of the following variables:
LE st = life expectancy at birth in state s in year t 13 ; expend st = the log of per capita medical expenditure in state s in year t;
and X includes a subset of the following variables:
adv_image% st = the fraction of standard or advanced Medicare imaging procedures performed in state s in year t that were advanced procedures; vint_medicaid_rx st = the mean vintage of Medicaid prescriptions in state s in year t; vint_medicaid_rx_fixed st = a fixed-weight index of the mean vintage of Medicaid prescriptions in state s in year t; vint_medicare_rx st = the mean vintage of Medicare drug treatments in state s in year t; md_research_qual st =; the fraction of physicians practicing in state s in year t who graduated from the top 60 medical schools ranked in terms of research; md_primcare_qual st = the fraction of physicians practicing in state s in year t who graduated from the top 60 medical schools ranked in terms of primary care; income st = the log of per capita personal income in state s in year t; edu st = an index of mean educational attainment of residents of state s in year t; health_cov st = the % of residents covered by health insurance in state s in year t; bmi_gt25 st = the % of residents with BMI >25 in state s in year t; now_smoke st = the % of residents who are current smokers in state s in year t; aids st−2 = the number of AIDS (Acquired Immune Deficiency Syndrome) cases reported per 100,000 population in state s in year t−2. In principle, there is some risk of feedback, or reverse causality, from life expectancy to some of the explanatory variables, especially mean income and education. Ceteris paribus, increases in life expectancy lead to an increase in the fraction of the population that is elderly. As shown in Fig. 8 , mean income and education of elderly people is significantly lower than that of non-elderly people. Hence unobserved shocks that increase a state's longevity could reduce its mean income and education, causing a downward bias in the coefficients of these variables. However, the share of the population that is elderly need not be increasing faster in states with larger increase in life expectancy; these states could have higher birth and/or net immigration rates.
In practice, the share of the population that is elderly is increasing faster in states with larger increase in life expectancy, but the relationship is not very strong. By using estimates of this relationship and the age profiles shown in Fig. 8 , we obtained estimates of the feedback effect of life expectancy on income and education, via population age structure. These calculations indicated that the downward biases in the income and education coefficients in the longevity equations would be extremely small.
Data sources and descriptive statistics
Life expectancy. The government does not publish data on life expectancy, by state, so we constructed estimates using data on the number of deaths by age group, year, and state of residence from the Multiple Cause-of-Death Mortality Data from the National Vital Statistics 14 Murray et al. (2006) also computed state and local estimates of life expectancy. 15 We computed life expectancy using the following age classification: under 1 year, 1-4 years, 5-9 years, 10-14 years, 15-19 years, 20-24 years, 25-29 years, 30-34 Service counts for drugs should be reported using pricing units, e.g. J0120: Injection, Tetracycline up to 250 mg. In this example, 250 mg = 1 pricing unit or service. If the injection were for 500 mg then the pricing unit or service would be equal to 2, i.e. 500 mg/250 mg = 2 pricing units or services. Many carriers are reporting the milligrams in the service count and MTUS Fields, e.g. 250 mg instead of 1 pricing unit. As a result the number of services are inflated, thereby deflating the average allowed charge. 16 These reporting errors appear to cause spurious fluctuations in aggregate Medicare drug treatment service counts, but not in expenditures. Therefore, while we believe that a quantity-weighted vintage index is preferable to an expenditure-weighted index, due to errors in reporting service counts we will use an expenditure-weighted index of Medicare drug treatments.
Data on e da were obtained from the ndc_denorm table in the Multum Lexicon database. Demographic characteristics and behavioral risk factors. Data on body mass index (BMI), current smoking participation, health insurance coverage, and educational attainment were obtained from the Behavioral Risk Factor Surveillance System (BRFSS), which is the world's largest telephone survey. The BRFSS was established by the CDC in 1984, and was designed to collect state-level data. By 1994, all states, the District of Columbia, and three territories were participating in the BRFSS.
Data on the incidence of AIDS (the number of AIDS cases reported by state and local health departments) were obtained from the CDC's AIDS Public Information Data Set (http://www. cdc.gov/hiv/software/apids.htm). This data set contains counts of AIDS, by demographics; location (region and selected metropolitan areas); case-definition; month/year and quarteryear of diagnosis, report, and death (if applicable); and HIV exposure group (risk factors for AIDS). The data set covers the period 1981-2002. As noted above, the measure of aids incidence we will include in our model of life expectancy will be the number of AIDS cases reported per 100,000 population lagged two years. Using this measure allows us to have the sample period end in 2004 rather than 2002. Also, Lichtenberg (2006b) provides evidence that even before highly-active retroviral therapy was introduced in the mid-1990s, life expectancy of AIDS patients at time of diagnosis was 3.7 years, so overall life expectancy may depend on lagged AIDS incidence more than it depends on contemporaneous AIDS incidence. 17 Table 6 shows population-weighted sample means of the variables included in Eq. 1, by year. Figure 10 shows the increase in the fixed-weighted drug vintage index 1991-2004, by state. 
Empirical results

Life expectancy
Estimates of models of life expectancy at birth are shown in the top half of Table 7 . The dependent variable in models 1-3 is life expectancy at birth. 18 The three models include different sets of indicators of the quality of medical care. Model 1 includes the basic Medicaid drug vintage measure vint_medicaid_rx (with changing therapeutic-class weights) and both measures of physician quality (md_primcare_qual and md_research_qual). Model 2 includes the fixedweight Medicaid drug vintage measure vint_medicaid_rx_fixed (with fixed therapeutic-class weights) and both measures of physician quality (md_primcare_qual and md_research_qual). Model 3 includes the fixed-weight Medicaid drug vintage measure and just the primary-care measure of physician quality. With only one exception, all of the indicators of the quality of medical care have positive and statistically significant effects on life expectancy in all three models. 19 In all three models, the advanced imaging coefficient is positive and highly significant ( p-value ≤ .003). This signifies that life expectancy increased more rapidly (and that the age-standardized mortality rate declined more rapidly) in states in which the fraction of Medicare imaging procedures that were advanced procedures increased more rapidly. Below we will discuss the magnitude of the estimated effect of the increased relative utilization of advanced imaging procedures on life expectancy. But first we will review the signs and significance of the other variables included in models 1-3.
The coefficients on both the basic Medicaid drug vintage measure (in model 1) and the fixed-weight Medicaid drug vintage measure (in models 2 and 3) are positive and highly significant. The vintage of Medicare drug treatments also has a positive and highly significant effect. Since expenditure on self-administered drugs is much larger than expenditure on provider-administered drugs, it is not surprising that the coefficients on Medicare drug vintage are much smaller than the coefficients on Medicaid drug vintage.
Although the research-quality of medical schools attended by physicians is insignificant in model 1 and only marginally significant in model 2, the primary-care-quality of medical schools attended by physicians is positive and significant in all three models. Almost three fourths of the medical school primary care quality ranking is based on the following criteria: peer assessment score, assessment score by residency directors, student selectivity, faculty resources, mean MCAT score, mean undergraduate GPA, and acceptance rate. States in which the primary-care-quality of medical schools attended by physicians declined more slowly had larger increases in life expectancy. Now let's consider the effects of three behavioral risk factors-obesity, AIDS, and smoking-on life expectancy. As one would expect, the coefficient on the fraction of the The estimates are weighted least-squares estimates, weighting by state population. All equations include fixed state effects and fixed year effects. Standard errors are clustered within states population with a BMI greater than 25 and the coefficient on the AIDS incidence rate are negative and highly significant in models 1-3. States with below-average increases in overweight/obesity prevalence and above-average declines in AIDS incidence had above-average increases in life expectancy during the period 1991-2004. Although the coefficient on smoking has the expected negative sign in all three models, it is insignificant in models 1 and 2 and only marginally significant ( p-value = .09) in model 3. Models 1-3 include three additional variables-health insurance coverage, educational attainment, and per capita income-that might be expected to affect life expectancy. At the state level, long-term changes in life expectancy seem to be uncorrelated with changes in both health insurance coverage and educational attainment. 20 The life expectancy of a state's residents appears to depend on education, but it is the quality of its physicians' medical education, not the number of years of schooling of state residents that matters.
Many studies have found a positive correlation between (the level of) socioeconomic status (education or income) and (the level of) life expectancy. However, there is good reason to believe that cross-sectional correlations between longevity and either education or income substantially overestimate the effect of socioeconomic status per se on longevity. For example, the positive correlation between income and longevity may reflect the effect of health on income ("reverse causality") as well as the effect of income on health.
Similarly, Almond and Mazumder (2006) argue that, "although it is well known that there is a strong association between education and health, much less is known about how these factors are connected, and whether the relationship is causal." Lleras-Muney (2005) provided perhaps the strongest evidence that education has a causal effect on health. Using state compulsory school laws as instruments, Lleras-Muney found large effects of education on mortality. Almond and Mazumder (2006) revisited these results, noting they are not robust to state time trends, even when the sample is vastly expanded and a coding error rectified. They employed a dataset containing a broad array of health outcomes and found that when using the same instruments, the pattern of effects for specific health conditions appears to depart markedly from prominent theories of how education should affect health. They also found suggestive evidence that vaccination against smallpox for school age children may account for some of the improvement in health and its association with education. This raised concerns about using compulsory schooling laws to identify the causal effects of education on health.
During the period 2000-2006, life expectancy at birth increased by 0.9 years, from 76.8 to 77.7 (Heron et al. 2009 ). Educational attainment also increased: the fraction of adults who had attended at least some college increased from 51.0% in 2000 to 53.7% in 2006. 21 But the most recent (and largest) estimates of education-related longevity differences, which for reasons discussed above are likely to overstate the effect of education on longevity, imply that increased educational attainment would have increased U.S. life expectancy by only 0.10-0.19 years during the period 2000-2006. 22 The coefficient on per capita income is negative and significant: states with high income growth had smaller longevity increases, ceteris paribus. Some previous investigators have also found evidence of a non-monotonic or even inverse relationship between income and longevity. Uchida et al. (1992) found that "for [Japanese] females high income was the factor significantly decreasing life expectancy at 65 years of age in 1980." Hupfeld (2008) theoretically derived a non-monotonic relationship between income and longevity, based on heterogeneous elasticities of labor supply and otherwise standard assumptions. He analyzed this relationship empirically for pensioners in the public pension system in Germany, and find 20 The nature of the effect of health insurance coverage on life expectancy is not entirely clear on theoretical grounds. Some analysts argue that people without health insurance receive necessary medical care, but that medical care is provided to them in an inefficient manner, e.g. in emergency rooms. Also, low health insurance coverage could be partly due to decisions by young, healthy people not to enroll in health plans. In that case, increases in coverage could be inversely correlated with increases in life expectancy. 21 Source: Meara et al. (2008) report that data from the National Longitudinal Mortality Study imply that, during the period 1991-1998, life expectancy at age 25 of people with any college education was 3.7 years higher than that of people with no college education. Data from Multiple Cause of Death files and census data imply that, in the year 2000, life expectancy at age 25 of people with any college education was 7.0 years higher than that of people with no college education. that "the relationship between income and life expectancy is indeed non-monotonic for major sub-groups in the data." And Ruhm (2004) argued that "although health is conventionally believed to deteriorate during macroeconomic downturns, the empirical evidence supporting this view is quite weak and comes from studies containing methodological shortcomings that are difficult to remedy. Recent research that better controls for many sources of omitted variables bias instead suggests that mortality decreases and physical health improves when the economy temporarily weakens. This partially reflects reductions in external sources of death, such as traffic fatalities and other accidents, but changes in lifestyles and health behaviors are also likely to play a role." Now we will use the estimates of the parameters of models 1-3 to estimate the 1991-2004 change in life expectancy that was attributable to each of the factors included in the models. The change attributable to a factor X is calculated as follows: β (X 2004 − X 1991 ), where β is the coefficient on that factor, and X 2004 and X 1991 are the population-weighted mean values of X in 2004 and 1991, respectively. These calculations are shown in Table 8 . Between 1991 and , life expectancy at birth increased 2.37 years. 23 The estimates imply that the increased use of advanced imaging technology increased life expectancy by 0.62-0.71 years during this period. The coefficient on the basic Medicaid drug vintage measure (vint_medicaid_rx) in model 1 implies that use of newer outpatient prescription drugs increased life expectancy by 1.26 years. The coefficient on the fixed-weight Medicaid drug vintage measure (vint_medicaid_rx_fixed) in models 2 and 3 implies that the increase in life expectancy attributable to use of newer outpatient prescription drugs was about 20% smaller: 0.96-1.08 years. The vint_medicare_rx coefficients imply that use of newer provider-administered drugs increased life expectancy by 0.48-0.54 years. Overall, therefore, use of newer self-and provider-administered drugs increased life expectancy by about 1.5 years.
Although the average values of the first two indicators of the quality of medical care increased during the period 1991-2004, the average value of the quality of medical schools attended by practicing physicians declined. Model 2 implies that the decline in both primarycare and research quality reduced life expectancy by 0.47 years; Model 3, which includes only the primary-care quality measure (the research quality measure is only marginally significant in model 2) implies that the decline in primary-care quality reduced life expectancy by 0.28 years.
Another factor that apparently reduced longevity growth during the period 1991-2004 was the rise from 44% to 59% in the fraction of the population that was overweight or obese. The estimates imply that this trend reduced the increase in life expectancy by.58-.68 years. Research conducted by the CDC to estimate mortality attributable to obesity has yielded findings consistent with this. Flegal et al. (2005) estimated deaths associated with underweight (body mass index [BMI] <18.5), overweight (BMI 25 to <30), and obesity (BMI 30) in the United States in 2000. They found that "underweight and obesity, particularly higher levels of obesity, were associated with increased mortality relative to the normal weight category."
The increase in the obesity risk factor was partly offset by a decline in another risk factor-the incidence of AIDS, which is estimated to have increased life expectancy by.18-.20 years. The estimates also suggest that the small decline in smoking prevalence may have increased life expectancy by about 0.10 years. 24 The estimates imply that this 19% increase in income reduced life expectancy by.34-.43 years. The sum of the contributions of all of the factors to the increase in life expectancy is in the 0.85-1.32 year range. Consequently, between 1.05 and 1.52 years of the 2.37-year increase in life expectancy is unexplained (i.e., captured by the year fixed effects).
Per capita medical expenditure
Estimates of models of (the log of) per capita personal health care expenditure are shown in the bottom half of Table 7 . These models include the same regressors as the life expectancy models in the top of the table. None of the coefficients on advanced imaging, drug vintage, or physician quality are statistically significant. This indicates that, although states with larger increases in the quality of diagnostic procedures, drugs, and physicians had larger increases in life expectancy, they did not have larger increases in per capita medical expenditure. This may be the case because, while newer diagnostic procedures and drugs are more expensive than their older counterparts, they may reduce the need for costly additional medical treatment. The absence of a correlation across states between medical innovation and expenditure growth is inconsistent with the view expressed by the Kaiser Family Foundation (2007), citing Rettig (1994) , that "advances in medical technology have contributed to rising overall U.S. health care spending."
The prevalence of obesity and smoking do not appear to affect per capita medical expenditure, but the incidence of AIDS has a significant positive effect. This is to be expected, since Duggan and Evans (2008) estimated that in California during the period 1994-2003, average annual Medicaid medical expenditure (the sum of pharmaceutical, outpatient and inpatient expenditure) per AIDS patient was about $18,800.
Increased health insurance coverage is associated with lower growth in per capita medical expenditure. One possible explanation is that lack of employer-based health insurance (which may result from employment in high-turnover industries) causes under-investment in the health of workers and higher medical expenditure in retirement. Fang and Gavazza (2007) found that employers in industries with high turnover rates are much less likely to offer health insurance to their workers, and that individuals who were employed in high turnover industries have higher medical expenditure when retired.
Growth in per capita medical expenditure is also positively correlated with growth in educational attainment and (more weakly) with income growth. Many previous studies have shown that medical care is a normal good (income elasticity greater than zero); some studies (Gerdtham and Jonsson (2000) ) suggest that it is a luxury good (income elasticity greater than one).
Robustness checks
Now I will present estimates of some additional life expectancy equations to assess the robustness of the estimates presented in Table 7 . These additional estimates are shown in Table 9 .
The life expectancy models presented in Table 7 include measures of the quality, but not the quantity, of medical care. Health expenditure is probably the best single measure of the quantity of medical care. If extremely reliable risk-adjustment were possible, one might expect to observe a positive correlation between health expenditure and outcomes such as life expectancy: if there were two individuals with exactly the same initial health status and medical conditions, the one subsequently receiving more medical care would be expected to have better outcomes. In practice, however, such reliable risk-adjustment is not feasible. Moreover, individuals with worse initial health status are likely to subsequently receive more medical care (which is unlikely to fully compensate for their worse initial health). (For example, both health expenditure and mortality risk rise with age.) Therefore, in the absence of extremely reliable risk-adjustment (which is rarely possible), we should not be surprised to observe a negative correlation between health expenditure and health outcomes.
The first model in Table 9 (model 7) is the same as model 3 in Table 7 , i.e. it does not include health expenditure. The second model in Table 9 (model 8) includes the log of per capita health expenditure (health_expend). The coefficient on health_expend is negative and close to statistically significant ( p-value = .078). This provides weak support for the hypothesis that states with higher per capita health expenditure growth had lower longevity growth. This may be due to the fact that the states with high per capita health expenditure growth tended to be states that experienced large, negative, exogenous "health shocks." If so, including health_expend in the model helps to control for these health shocks. But including health_expend in the model has virtually no effect on the healthcare quality coefficients. This is not surprising, since we have already shown that states with larger increases in the quality of diagnostic procedures, drugs, and physicians did not have larger increases in per capita medical expenditure. When health_expend is included in the model, the coefficient on per capita income becomes statistically insignificant.
The dependent variable in the life expectancy models presented in Table 7 is life expectancy at birth. The dependent variable in model 9 of Table 9 is life expectancy at age 1. 10: 1994 10: , 1997 10: , 1998 10: , 2000 10: , 2001 10: , 2003 10: only Model 11: control for computer use (1994 10: , 1997 10: , 1998 10: , 2000 10: , 2001 10: , 2003 This model therefore eliminates the influence of infant mortality. Eliminating the influence of infant mortality also has virtually no effect on the healthcare quality coefficients. 25 This is not surprising, since only about one-tenth of the increase in life expectancy at birth during this period was due to a reduction in infant mortality. Three of our four healthcare quality indicators measure the rate of adoption of medical innovations. It is conceivable that the rate of adoption of medical innovations is positively correlated, across states, with the rate of adoption of nonmedical innovations, which might also influence longevity growth. Measuring the adoption of most innovations, by state and year, is not feasible, but there is one important innovation whose diffusion can be tracked: use of personal computers in the home. In six years during the period 1994-2003, respondents to the Current Population Survey indicated whether or not they used a computer at home. The percent of people using computers at home (use_computer) increased from 25% in 1994 to 62% in 2003. The rate of increase varied considerably across states.
The use_computer measure is clearly subject to considerable sampling error, and including it in the life expectancy model reduces the number of observations by 57%. The effect of the sample size reduction is shown in Model 10, which has the same specification as Model 8 (i.e. it does not include use_computer), but is estimated using data only for the years in which use_computer was measured. The imaging coefficient remains highly significant, the Medicaid (outpatient) drug coefficient is marginally significant ( p-value = .084), and the Medicare drug coefficient is insignificant. Model 11 includes the use_computer variable. Its coefficient is far from statistically significant, and the coefficients on the healthcare quality coefficients in Model 11 are very similar to those in Model 10. This indicates that controlling for the adoption of an important nonmedical innovation has little influence on the estimated effects of medical innovation adoption on life expectancy. However, due to data limitations, the power of this test is not very high.
Summary
The rate of increase of longevity has varied considerably across U.S. states since 1991. This paper has examined the effect of the quality of medical care, behavioral risk factors, and other variables on life expectancy and medical expenditure using longitudinal state-level data.
We examined the effects of three different measures of the quality of medical care. The first is the average quality of diagnostic imaging procedures, defined as the fraction of procedures that are advanced procedures. The second is the average quality of practicing physicians, defined as the fraction of physicians that were trained at top-ranked medical schools. The third is the mean vintage (FDA approval year) of outpatient and inpatient prescription drugs.
We also examined the effects on longevity of three important behavioral risk factorsobesity, smoking, and AIDS incidence-and other variables-education, income, and health insurance coverage-that might be expected to influence longevity growth. Our econometric approach controlled for the effects of unobserved factors that vary across states but are relatively stable over time (e.g. climate and environmental quality), and unobserved factors that change over time but are invariant across states (e.g. changes in Federal government policies).
Our indicators of the quality of diagnostic imaging procedures, drugs, and physicians almost always had positive and statistically significant effects on life expectancy. Life expectancy increased more rapidly in states where (1) the fraction of Medicare diagnostic imaging procedures that were advanced procedures increased more rapidly; (2) the vintage of self-and provider-administered drugs increased more rapidly; and (3) the quality of medical schools previously attended by physicians increased more rapidly.
Between 1991 and 2004, life expectancy at birth increased 2.37 years. The estimates imply that, during this period, the increased use of advanced imaging technology increased life expectancy by 0.62-0.71 years, use of newer outpatient prescription drugs increased life expectancy by 0.96-1.26 years, and use of newer provider-administered drugs increased life expectancy by 0.48-0.54 years. The decline in the average quality of medical schools previously attended by physicians reduced life expectancy by 0.28-0.47 years.
The rise from 44 to 59% in the fraction of the population that was overweight or obese reduced the increase in life expectancy by .58-.68 years. The decline in the incidence of AIDS is estimated to have increased life expectancy by.18-.20 years. The small decline in smoking prevalence may have increased life expectancy by about 0.10 years.
Growth in life expectancy was uncorrelated across states with health insurance coverage and education, and inversely correlated with per capita income growth. The 19% increase in real per capita income is estimated to have reduced life expectancy by .34-.43 years. The sum of the contributions of all of the factors to the increase in life expectancy is in the 0.85-1.32 year range. Consequently, between 1.05 and 1.52 years of the 2.37-year increase in life expectancy is unexplained.
We performed several tests of the robustness of the life expectancy model. Controlling for per capita health expenditure (the "quantity" of healthcare), and eliminating the influence of infant mortality, had virtually no effect on the healthcare quality coefficients. Controlling for the adoption of an important nonmedical innovation also had little influence on the estimated effects of medical innovation adoption on life expectancy.
Although states with larger increases in the quality of diagnostic procedures, drugs, and physicians had larger increases in life expectancy, they did not have larger increases in per capita medical expenditure. This may be the case because, while newer diagnostic procedures and drugs are more expensive than their older counterparts, they may reduce the need for costly additional medical treatment. The absence of a correlation across states between medical innovation and expenditure growth is inconsistent with the view that advances in medical technology have contributed to rising overall U.S. health care spending. Increased health insurance coverage is associated with lower growth in per capita medical expenditure.
The medical school research model is based on a weighted average of eight indicators, and the primary-care model is based on seven indicators. Both rankings are based on a weighted average of indicators, four of the data indicators are used in both the research and primary-care ranking model. The research model factors in research activity; the primary-care model adds a measure of the proportion of graduates entering primary-care specialties.
Quality Assessment (weighted by.40) Peer Assessment Score (.20 for the research medical school model,.25 for the primary-care medical school model) In the fall of 2007, medical and osteopathic school deans, deans of academic affairs, and heads of internal medicine or the directors of admissions were asked to rate programs on a scale from "marginal" (1) to "outstanding" (5). Survey populations were asked to rate program quality for both research and primary-care programs separately on a single survey instrument. Those individuals who did not know enough about a school to evaluate it fairly were asked to mark "don't know." A school's score is the average of all the respondents who rated it. Responses of "don't know" counted neither for nor against a school. About 48% of those surveyed responded.
Assessment Score by Residency Directors (.20 for the research medical school model,.15 for the primary-care medical school model) In the fall of 2007, residency program directors were asked to rate programs on two separate survey instruments. One survey dealt with research and was sent to a sample of residency program directors in fields outside primary care, including surgery, psychiatry, and radiology. The other survey involved primary care and was sent to residency directors in the fields of family practice, pediatrics, and internal medicine. Survey recipients were asked to rate programs on a scale from "marginal" (1) to "outstanding" (5). Those individuals who did not know enough about a program to evaluate it fairly were asked to mark "don't know." A school's score is the average of all the respondents who rated it. Responses of "don't know" counted neither for nor against a school. About 25% of those surveyed for research medical schools responded; 18% responded for primary-care. Student Selectivity (.20 Overall Rank: Indicators were standardized about their means, and standardized scores were weighted, totaled, and rescaled so that the top school received 100; other schools received their percentage of the top score.
Specialty Rankings: The rankings are based solely on ratings by medical school deans and senior faculty from the list of schools surveyed. They each identified up to 10 schools offering the best programs in each specialty area. Those receiving the most nominations appear here.
Appendix B
Correlation across states between changes in the vintage of Medicaid and non-Medicaid prescriptions
This appendix describes a test of the hypothesis that the extent of utilization of new drugs in the Medicaid program is strongly correlated with the extent of utilization of new drugs in general. We had access to data from a private company, NDCHealth, on the number of prescriptions, by NDC code, state (and five U.S. territories), month (January 2001 -December 2003 , and payer (Medicaid, other third party, and cash), for six important therapeutic classes of drugs: antidepressants, antihypertensives, cholesterol-lowering drugs, diabetic drugs, osteoporosis/ menopause drugs, and pain management medications. Here are some summary statistics: 
where VINT_MEDICAID it = the mean vintage (FDA approval year) of Medicaid rx's in state i in month t; Y it = the mean vintage of all rx's or of non-Medicaid (third-party and cash) rx's in state i in month t; α i = a fixed effect for state i; δ t = a fixed effect for year t; ε it = a disturbance.
Two alternative measures of vintage were used: the mean FDA approval year, and the share of prescriptions containing active ingredients approved after 1980. Estimates of Eq. 1 are shown in Table 1 . In all four equations, the estimate of π is positive and highly statistically significant ( p-value <.00001). This indicates that the extent of utilization of new drugs in the Medicaid program is strongly correlated with the extent of utilization of new drugs in general. The vintage of non-Medicaid (and all) rx's tended to increase more in states with larger increases in the vintage of Medicaid rx's (Appendix Table 10 ).
